Central Core DiseaseREADYCOMNCT06157268
The Natural History and Muscle Fatigability of Patients With Congenital Myopathies.
An observational study of Central Core Disease and Multi-Minicore Disease, run by Radboud University Medical Center at 2 sites in Netherlands.
Trial summary
Core myopathies (CCD/MmD), nemaline myopathies (NEM) and centronuclear myopathies (CNM) are three types of rare congenital myopathies. Not much is known about the natural history and no curative treatment is available for these groups. Also patients report fatigability as one of their symptoms. Read more about this study
- Who is it for?
- Ages 2 years and older
- Conditions the study is for
- Central Core Disease, Multi-Minicore Disease, Nemaline Myopathy
- What is being tested?
- Natural history and non therapeutical therapy
- How many people
- 100 participants
- Where
- 2 sitesNetherlands
- Study dates
- 28 Mar 2024to Nov 2026
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 2 years and older
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: 45 patients will be included in the natural history study and 75 patients in the fatigability study, with some patients in both studies. The participants will be equally divided over three groups (CCD/MmD, NEM, CNM). Patients will be identified through patient databases of the Radboudumc and UMC Utrecht and patient groups. If more than 15/25 patients per group are willing to participate, we will select patients based on age and severity to have a good representation of the entire/complete disease spectrum.
Who may be able to join
- 2 years or older
- Willing and able to complete the measurement protocol
- Willing and able to travel to Nijmegen and Utrecht
- Dutch-speaking
- Genetically-confirmed congenital myopathy (CCD/MmD, NEM, and CNM)
- 8-60 years old
Show all 11Show fewer
- Willing and able to complete the measurement protocol
- Willing and able to travel to Nijmegen and Utrecht
- Dutch-speaking
- Genetically-confirmed congenital myopathy (CCD/MmD, NEM, and CNM)
- Willing to stop taking pyridostigmine and/or salbutamol 24 hours before the visit.
Who cannot join
- Other neuromuscular, psychiatric or neurological disorders.
Trial locations and contacts
2 sites in 1 country. Contact the study team or a site near you to ask about taking part.
Netherlands2 sites, 2 recruiting
- Recruiting
Radboudumc
Nijmegen, Gelderland, 6500HB
Nicol Voermans, +31650155770, Nicol.Voermans@radboudumc.nl
Nicol Voermans, MD PhD
- Not yet recruiting
UMC Utrecht
Utrecht, 3584 CX
Ludo van der Pol, Prof. Dr., 0887551546, wpol2@umcutrecht.nl
Ludo van de Pol, Prof. Dr.
About this study
Official title: Trial Readiness and Trial Fitness for Congenital Myopathies: a 2-year Prospective Natural History Study Including a Cross-sectional Study on Muscle Fatigability
Core myopathies (CCD/MmD), nemaline myopathies (NEM) and centronuclear myopathies (CNM) are three types of rare congenital myopathies. Not much is known about the natural history and no curative treatment is available for these groups. Also patients report fatigability as one of their symptoms. The goal of this observational study is to study the natural history during 24 months to achieve trial readiness and to study the muscle fatigability in CCD/MmD, NEM and CNM.
Read the detailed description
Rationale: Patients with CCD/MmD, NEM and CNM report symptoms of weakness in the arms and legs. Other symptoms include weakness of the respiratory, facial and swallowing muscles. No treatments are available for congenital myopathies (CM) to slow down or cure the disease. A few type I-II trials have taken place and more are expected. Therefore it is important to reach trial readiness. To create trial readiness, there is a need for natural history study to create a detailed report of the disease course and a selection of the most sensitive clinical and functional outcome measures and biomarkers. Besides muscle weakness, several patients report muscle fatigability. This has not been investigated systematically in CM. The lack of evidence calls for a cross-sectional study assessing muscle fatigability and neuromuscular transmission in CM.
Objectives: i) To assess the natural disease course of CCD/MmD, NEM and CNM during 24 months. ii) To select relevant and sensitive clinical and functional outcome measures and biomarkers. iii) To assess the severity of muscle fatigability in CCD/MmD, NEM and CNM.
Study design: Patients with a genetically confirmed CCD/MmD, NEM or CNM will be able to participate in this study. The study consist of 2 parts. Part 1: a prospective cohort study with 5 visits every 6 months, for a total of 2 years. 45 patients will be included for this part. Part 2: an observational study with 2 visits. For this part 75 patients will be included. There will be an overlap in patients for the two parts. So a total of approximately 100 patients will be included. A large set of tests will be performed to assess the full capabilities of the patient, e.g. muscle strength/endurance, muscle imaging (MRI/ultrasound), activities, walking ability, quality of life, muscle fatigability and the feeling of fatigue.
- Being tested
- Natural history and non therapeutical therapy
- Keywords
- Natural history study, Outcome measures, Congenital myopathy, Muscle disease
- Medical subject headings
- Myopathy, Central Core, Minicore Myopathy with External Ophthalmoplegia, Myopathies, Nemaline, Myopathies, Structural, Congenital, Myotonia Congenita, Muscular Diseases
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Natural history and non therapeutical therapyOther
This study concerns a natural history study part and a muscle fatigability part.
For the natural history study no interventions will be used. For the muscle fatigability part non therapeutical therapies will be used. This includes endurance tests, isokinetic dynamometry and repetitive nerve stimulation.
| Study group | Role | What they receive |
|---|---|---|
| Core myopathies | Patients with a genetically confirmed core myopathy Receives: Other: Natural history and non therapeutical therapy | |
| Nemaline myopathy | Patients with a genetically confirmed nemaline myopathy Receives: Other: Natural history and non therapeutical therapy | |
| Centronuclear myopathy | Patients with a genetically confirmed centronuclear myopathy Receives: Other: Natural history and non therapeutical therapy |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change of Motor Function Measure (MFM)
Global motor functioning. The main outcome is the change in MFM score over a period of 2 years. The scores of the patients will also be compared to reference values.
Measured: Change from baseline at 6, 12, 18 and 24 months
Endurance shuttle test - fatigability part
Patients walk/move blocks/move pegs at a personalised set speed. The main outcome is if the patient drops out due to the speed being too low. If the patient drops out the time until dropout is noted.
Measured: At assessment 1 or 2 of the fatigability part of the study. Which day is dependent on the preference of the patient and planning possibilities.
Secondary outcomes (40)
Change of 6-minute walk test (6MWT) (5 years and older)
How far the patient can walk in 6 minutes. The first and last minute will be compared to each other.
Measured: Change from baseline at 6, 12, 18 and 24 months
Accelerometry - change of extent and intensity of physical activity in daily life (all ages)
Physical activity in daily life will be assessed by wearing an wrist worn accelerometer (GENEActiv original devices) for 7 days.
Measured: Change from baseline at 6, 12, 18 and 24 months
Change of bone density (DEXA scan) (6 years and older)
The bone density of the spine and hip will be measured by a DEXA scan.
Measured: Change from baseline at 24 months
Change of graded and timed rise from floor (5 years and older)
The time it takes to rise from the floor
Measured: Change from baseline at 6, 12, 18 and 24 months
Handheld dynamometry (5 years and older)
Maximal voluntary isometric contraction will be measured by handheld dynamometry (m. biceps brachii, m. quadriceps, grip strength, all bilaterally)
Measured: Change from baseline at 6, 12, 18 and 24 months
Creatine Kinase
Blood level of Creatine Kinase
Measured: At baseline
Vitamin D3
Blood level of Vitamin D3
Measured: At baseline
Calcium
Blood level of calcium
Measured: At baseline
Liver function panel
Blood level of bilirubin, alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, gamma-glutamyltransferase GGT, albumin, bile acids and full blood count.
Measured: At baseline
Manual muscle testing (MMT) (5 years and older)
Muscle power of individual muscle groups can be assessed by muscle power measurements and graded in correspondence with the Medical Research Council (MRC) scale.
Measured: Change from baseline at 6, 12, 18 and 24 months
Change in muscle fattening by quantitative lower extremity muscle MRI (10 years and older)
A lower extremity muscle MRI will be performed in participants who are able to lie supine and still for 20 minutes and who are not dependent on respiratory equipment. Muscle fattening will be assessed by Regions of Interest (ROIs) (quantitative) and modified Mercuri score (semi-quantitative).
Measured: Change from baseline at 24 months
Change of muscle atrophy by quantitative lower extremity muscle MRI (10 years and older)
A lower extremity muscle MRI will be performed in participants who are able to lie supine and still for 20 minutes and who are not dependent on respiratory equipment. Atrophy will be assessed by muscle volume score (semi-quantitative).
Measured: Change from baseline at 24 months
Change in muscle atrophy (cm) assessed by muscle ultrasound (all ages)
Muscle atrophy of the leg, arm, back, abdominal muscles and diaphragm will be assessed by muscle ultrasound.
Measured: Change from baseline at 24 months
Change in muscle fattening (echo-intensity) assessed by muscle ultrasound (all ages)
Muscle fattening of the leg, arm, back, abdominal muscles and diaphragm will be assessed by muscle ultrasound.
Measured: Change from baseline at 24 months
Range of motion (all ages)
The range of motion of the elbows, fingers, knees and ankles is noted bilaterally by goniometry.
Measured: Change from baseline at 6, 12, 18 and 24 months
Pulmonary function - change of forced vital capacity (percentage predicted) (5 years and older)
Obtained with handheld spirometry in sit and supine.
Measured: Change from baseline at 6, 12, 18 and 24 months
Pulmonary function - change of forced expiratory volume in the first second (5 years and older)
Obtained with handheld spirometry in sit and supine.
Measured: Change from baseline at 6, 12, 18 and 24 months
Pulmonary function - change of maximal expiratory pressure (cmH2O) (5 years and older)
Obtained with handheld device.
Measured: Change from baseline at 6, 12, 18 and 24 months
Pulmonary function - change of maximal inspiratory pressure (cmH2O) (5 years and older)
Obtained with handheld device.
Measured: Change from baseline at 6, 12, 18 and 24 months
Pulmonary function - change of sniff nasal inspiratory pressure (5 years and older)
Obtained with handheld device.
Measured: Change from baseline at 6, 12, 18 and 24 months
Vignos and Brooke scale (all ages)
The Brooke (score 1-6) and Vignos (score 1-10) scales provide ordinal data to assess the upper and lower extremity functions. A lower score indicates more functionality.
Measured: Change from baseline at 6, 12, 18 and 24 months
Isokinetic dynamometry (quadriceps and hamstrings or biceps and triceps) (8-60 years old) - fatigability part
Peak torque, time to peak torque, change in torque from first third to last third, acceleration time and deceleration time for 3, 5 and 30 repetitions at a set speed. For the 30 repetitions how many repetitions until failure is also noted.
Measured: At assessment 1 or 2 of the fatigability part of the study. Which day is dependent on the preference of the patient and planning possibilities.
Change in surface electromyography (EMG) amplitude and median frequency during isokinetic dynamometry with surface EMG (quadriceps and hamstrings or biceps and triceps) (8-60 years old) - fatigability part
On the quadriceps/hamstrings or biceps/triceps surface EMG amplitude and median frequency will be measured.
Measured: At assessment 1 or 2 of the fatigability part of the study. Which day is dependent on the preference of the patient and planning possibilities.
Repetitive nerve stimulation (RNS) (8-60 years old) - fatigability part
We will stimulate the n. ulnaris, n. accesorius and n. facialis at 3 Hz to measure the m abductor digiti minimi, m. trapezius and m nasalis. The decrement/increment will be determined by the compound muscle action potential amplitude and area.
The RNS will be performed before and after 60 seconds of voluntary contraction.
Measured: At assessment 1 or 2 of the fatigability part of the study. Which day is dependent on the preference of the patient and planning possibilities.
Checklist individual strength (CIS) questionnaire fatigue subscale (18 years and older)
The CIS is a questionnaire rating four subscales: subjective tiredness, concentration, motivation and physical activity. It consists of 20 items on a 7-point scale. We will use the Fatigue subscale. A CIS fatigue scale ≥ 35 points to severe fatigue.
Measured: Change from baseline at 6, 12, 18 and 24 months
Fatigue severity scale questionnaire (12 years and older)
Nine-questions scale about the impact of fatigue on the patient's life. Each item is scored on a 7 point scale. A higher score indicates greater fatigue/greater impact of fatigue on daily life.
Measured: Change from baseline at 6, 12, 18 and 24 months
PedsQL multidimensional fatigue scale (MFS) (2-17 years old)
The PedsQL MFS assesses subjective fatigue in three domains with 6 items each, namely General Fatigue Scale, Sleep/Rest Fatigue Scale, and Cognitive Fatigue Scale. Each item is scored on a three point scale ranging from not at all to a lot for children aged 5-7 and a five point scale from never to almost always for the others. Higher scores indicates less symptoms.
Measured: Change from baseline at 6, 12, 18 and 24 months
PROMIS Fatigue Short Form questionnaire (all ages)
Consists of 8 items representing the most informative items from the PROMIS item bank. The PROMIS Fatigue item banks assess a range of self-reported symptoms, from mild subjective feelings of tiredness to an overwhelming, debilitating, and sustained sense of exhaustion that likely decreases one's ability to execute daily activities and function normally in family or social roles. For patients younger than 18 a parent proxy is also available. The items are scored form 1-5 with a higher score indicating more fatigue.
Measured: Change from baseline at 6, 12, 18 and 24 months
McGill pain questionnaire (MPQ) (12 years and older)
The MPQ consists of 4 components: a pain word list to state the type and intensity of the pain, questions about the effect on daily life, a visual-analogue scale for pain intensity and questions about the location and course of the pain.
Measured: Change from baseline at 6, 12, 18 and 24 months
Wong-Baker Faces Pain Scale (2-11 years old)
The Wong-Baker Faces Pain Scale was originally created for children to help them communicate about their pain. It has six types of faces ranging from no hurt (0) tot hurts worst (10).
Measured: Change from baseline at 6, 12, 18 and 24 months
PedsQL generic quality of life (2-17 years old)
The PedsQL generic quality of life questionnaire consists of 8 items on physical functioning, 5 items on emotional functioning, 5 items on social functioning, and 5 items on school functioning. Each item is scored on a 0-4 scale. The items are reversed scored and linearly transformed to a 0-100 scale, so that higher scores indicate a better outcome.
Measured: Change from baseline at 6, 12, 18 and 24 months
Short Form 36 (SF36) quality of life scale (18 years and older)
The adult Quality of Life is measured by the SF36/RAND36 questionnaire. The SF36/RAND36 addresses eight concepts: physical functioning, bodily pain, role limitations due to physical health problems, role limitations due to personal or emotional problems, emotional well-being, social functioning, energy/fatigue, and general health perceptions. It also includes a single item that provides an indication of perceived change in health. It has a total of 36 items.
Measured: Change from baseline at 6, 12, 18 and 24 months
Activlim questionnaire (7-17 years old)
ACTIVLIM assesses the ability to perform 22 activities of daily life on a 3-point scale from impossible to easy. The questionnaires will be answered by the parents of the patient.
Measured: Change from baseline at 6, 12, 18 and 24 months
Impact on participation and autonomy (18 years and older)
Questionnaire about participation and autonomy in daily life with 41 questions on a ordinal 3- or 5-point likert scale. Higher scores indicate more obstacles in participation and autonomy.
Measured: Change from baseline at 6, 12, 18 and 24 months
Utrecht Scale for Evaluation of Rehabilitation-Participation (USER-P) (18 years and older)
USER-P Restrictions scale is a patients-reported outcome measures with 32 questions focusing on daily activities including school and work. Each item is scored on a 4-, 5-, and 6-point Likert scale. A higher score indicates more participation.
Measured: Change from baseline at 6, 12, 18 and 24 months
Borg rating scale of perceived exertion (5 years and older)
Borg Rating Scale of Perceived Exertion is a way of measuring physical activity intensity level. Perceived exertion is based on the physical sensations a person experiences during physical activity. It is scored 6-20 with a higher score indicating a greater perceived exertion.
Participants will be asked to score the intensity level at the beginning and at the end of the 6MWT.
Measured: Change from baseline at 6, 12, 18 and 24 months
Hospital anxiety and depression scale (18 years and older)
Questionnaire about the main complaints of anxiety and depression with 7 items each on a 4-point Likert scale. A higher score indicates more complaints.
Measured: Change from baseline at 6, 12, 18 and 24 months
PedsQL neuromuscular module (NMM) (2-17 years old)
The PedsQL NMM questionnaire consists of 25 questions in three domains: Neuromuscular disease, communication and family resources. Each item is scored on a 0-4 scale. The items are reversed scored and linearly transformed to a 0-100 scale, so that higher scores indicate a better outcome.
Measured: Change from baseline at 6, 12, 18 and 24 months
Resilience evaluation scale (18 years and older)
9-Item questionnaire on psychological resilience with each item being scored from 0-4, higher scores indicating greater resilience.
Measured: Change from baseline at 6, 12, 18 and 24 months
Effects of pyridostigmine and/or salbutamol (8-60 years old) - fatigability part
We will ask patients if they use pyridostigmine and/or salbutamol. If they use it we will ask how often, what the effects are and how long those effects last.
Measured: At baseline of the fatigability part of the study
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted5 Dec 2023
- Study start28 Mar 2024
- Primary completionNov 2026 (estimated)
- Study completionNov 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Central Core DiseaseStudies of the same condition, open and under way.
- More trials run by Radboud University Medical CenterThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 100 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Radboud University Medical Center
- Sponsor type
- University, hospital or other
- Collaborators
- UMC Utrecht
- Responsible party
- Sponsor
- Investigators
- Nicol Voermans, MD PhD, Principal investigator, Radboud University Medical Center
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06157268
- Sponsor's protocol ID
- NL83069.000.23
- Other IDs
- W.OR22-10
- Acronym
- READYCOM
- Status last verified
- Mar 2024
- First submitted
- 9 Nov 2023
- Last updated
- 19 Aug 2024
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided: Research data is open access shared upon publication, provided that this complies with privacy regulations. The Donders Repository is the default repository for sharing the investigators' data.
Publications
van de Camp SAJH, Brenninkmeijer R, van Doorn JLM, de Laat ECM, Pomp L, Stinissen L, Cameron D, Groothuis JT, van Alfen N, Jungbluth H, Erasmus CE, Bartels B, Wadman RI, Voet NBM, van der Pol WL, Voermans NC. READYCOM: protocol for a 2-year prospective natural history and cross-sectional muscle-fatigability study for improving trial readiness in congenital myopathies. BMJ Open. 2026 Aug 4;16(8):e119529. doi: 10.1136/bmjopen-2026-119529.
PubMed 42551994
Study at a glance
From the registry record, last updated by the sponsor on 19 Aug 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Trial Readiness and Trial Fitness for Congenital Myopathies: a 2-year Prospective Natural History Study Including a Cross-sectional Study on Muscle Fatigability
- ClinicalTrials.gov ID
- NCT06157268
- Acronym / sponsor ID
- READYCOM / NL83069.000.23
- Keywords
- Natural history study, Outcome measures, Congenital myopathy, Muscle disease
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 100 participants (estimated)
- Lead sponsor
- Radboud University Medical CenterUniversity, hospital or other
- Collaborators
- UMC Utrecht
- Study start
- 28 Mar 2024 (actual)
- Primary completion
- Nov 2026 (estimated)
- Study completion
- Nov 2026 (estimated)
- First posted
- 5 Dec 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Core myopathies (CCD/MmD), nemaline myopathies (NEM) and centronuclear myopathies (CNM) are three types of rare congenital myopathies. Not much is known about the natural history and no curative treatment is available for these groups. Also patients report fatigability as one of their symptoms. The goal of this observational study is to study the natural history during 24 months to achieve trial readiness and to study the muscle fatigability in CCD/MmD, NEM and CNM.
Detailed description
Rationale: Patients with CCD/MmD, NEM and CNM report symptoms of weakness in the arms and legs. Other symptoms include weakness of the respiratory, facial and swallowing muscles. No treatments are available for congenital myopathies (CM) to slow down or cure the disease. A few type I-II trials have taken place and more are expected. Therefore it is important to reach trial readiness. To create trial readiness, there is a need for natural history study to create a detailed report of the disease course and a selection of the most sensitive clinical and functional outcome measures and biomarkers. Besides muscle weakness, several patients report muscle fatigability. This has not been investigated systematically in CM. The lack of evidence calls for a cross-sectional study assessing muscle fatigability and neuromuscular transmission in CM.
Objectives: i) To assess the natural disease course of CCD/MmD, NEM and CNM during 24 months. ii) To select relevant and sensitive clinical and functional outcome measures and biomarkers. iii) To assess the severity of muscle fatigability in CCD/MmD, NEM and CNM.
Study design: Patients with a genetically confirmed CCD/MmD, NEM or CNM will be able to participate in this study. The study consist of 2 parts. Part 1: a prospective cohort study with 5 visits every 6 months, for a total of 2 years. 45 patients will be included for this part. Part 2: an observational study with 2 visits. For this part 75 patients will be included. There will be an overlap in patients for the two parts. So a total of approximately 100 patients will be included. A large set of tests will be performed to assess the full capabilities of the patient, e.g. muscle strength/endurance, muscle imaging (MRI/ultrasound), activities, walking ability, quality of life, muscle fatigability and the feeling of fatigue.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Core myopathies | – | Other: Natural history and non therapeutical therapyPatients with a genetically confirmed core myopathy |
| Nemaline myopathy | – | Other: Natural history and non therapeutical therapyPatients with a genetically confirmed nemaline myopathy |
| Centronuclear myopathy | – | Other: Natural history and non therapeutical therapyPatients with a genetically confirmed centronuclear myopathy |
Who may qualify
- Ages
- 2 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- 45 patients will be included in the natural history study and 75 patients in the fatigability study, with some patients in both studies. The participants will be equally divided over three groups (CCD/MmD, NEM, CNM). Patients will be identified through patient databases of the Radboudumc and UMC Utrecht and patient groups. If more than 15/25 patients per group are willing to participate, we will select patients based on age and severity to have a good representation of the entire/complete disease spectrum.
Key inclusion criteria (11 listed)
- 2 years or older
- Willing and able to complete the measurement protocol
- Willing and able to travel to Nijmegen and Utrecht
- Dutch-speaking
- Genetically-confirmed congenital myopathy (CCD/MmD, NEM, and CNM)
Key exclusion criteria (1 listed)
- Other neuromuscular, psychiatric or neurological disorders.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Natural history and non therapeutical therapyThis study concerns a natural history study part and a muscle fatigability part. For the natural history study no interventions will be used. For the muscle fatigability part non therapeutical therapies will be used. This includes endurance tests, isokinetic dynamometry and repetitive nerve stimulation. | Other | Centronuclear myopathy, Core myopathies, Nemaline myopathy |
Primary outcome
Change of Motor Function Measure (MFM)
Time frame: Change from baseline at 6, 12, 18 and 24 months
Global motor functioning. The main outcome is the change in MFM score over a period of 2 years. The scores of the patients will also be compared to reference values.
Endurance shuttle test - fatigability part
Time frame: At assessment 1 or 2 of the fatigability part of the study. Which day is dependent on the preference of the patient and planning possibilities.
Patients walk/move blocks/move pegs at a personalised set speed. The main outcome is if the patient drops out due to the speed being too low. If the patient drops out the time until dropout is noted.
40 secondary outcomes
Change of 6-minute walk test (6MWT) (5 years and older)
Time frame: Change from baseline at 6, 12, 18 and 24 months
Accelerometry - change of extent and intensity of physical activity in daily life (all ages)
Time frame: Change from baseline at 6, 12, 18 and 24 months
Change of bone density (DEXA scan) (6 years and older)
Time frame: Change from baseline at 24 months
Change of graded and timed rise from floor (5 years and older)
Time frame: Change from baseline at 6, 12, 18 and 24 months
Handheld dynamometry (5 years and older)
Time frame: Change from baseline at 6, 12, 18 and 24 months
Creatine Kinase
Time frame: At baseline
Vitamin D3
Time frame: At baseline
Calcium
Time frame: At baseline
Liver function panel
Time frame: At baseline
Manual muscle testing (MMT) (5 years and older)
Time frame: Change from baseline at 6, 12, 18 and 24 months
Change in muscle fattening by quantitative lower extremity muscle MRI (10 years and older)
Time frame: Change from baseline at 24 months
Change of muscle atrophy by quantitative lower extremity muscle MRI (10 years and older)
Time frame: Change from baseline at 24 months
Change in muscle atrophy (cm) assessed by muscle ultrasound (all ages)
Time frame: Change from baseline at 24 months
Change in muscle fattening (echo-intensity) assessed by muscle ultrasound (all ages)
Time frame: Change from baseline at 24 months
Range of motion (all ages)
Time frame: Change from baseline at 6, 12, 18 and 24 months
Pulmonary function - change of forced vital capacity (percentage predicted) (5 years and older)
Time frame: Change from baseline at 6, 12, 18 and 24 months
Pulmonary function - change of forced expiratory volume in the first second (5 years and older)
Time frame: Change from baseline at 6, 12, 18 and 24 months
Pulmonary function - change of maximal expiratory pressure (cmH2O) (5 years and older)
Time frame: Change from baseline at 6, 12, 18 and 24 months
Pulmonary function - change of maximal inspiratory pressure (cmH2O) (5 years and older)
Time frame: Change from baseline at 6, 12, 18 and 24 months
Pulmonary function - change of sniff nasal inspiratory pressure (5 years and older)
Time frame: Change from baseline at 6, 12, 18 and 24 months
Vignos and Brooke scale (all ages)
Time frame: Change from baseline at 6, 12, 18 and 24 months
Isokinetic dynamometry (quadriceps and hamstrings or biceps and triceps) (8-60 years old) - fatigability part
Time frame: At assessment 1 or 2 of the fatigability part of the study. Which day is dependent on the preference of the patient and planning possibilities.
Change in surface electromyography (EMG) amplitude and median frequency during isokinetic dynamometry with surface EMG (quadriceps and hamstrings or biceps and triceps) (8-60 years old) - fatigability part
Time frame: At assessment 1 or 2 of the fatigability part of the study. Which day is dependent on the preference of the patient and planning possibilities.
Repetitive nerve stimulation (RNS) (8-60 years old) - fatigability part
Time frame: At assessment 1 or 2 of the fatigability part of the study. Which day is dependent on the preference of the patient and planning possibilities.
Checklist individual strength (CIS) questionnaire fatigue subscale (18 years and older)
Time frame: Change from baseline at 6, 12, 18 and 24 months
Fatigue severity scale questionnaire (12 years and older)
Time frame: Change from baseline at 6, 12, 18 and 24 months
PedsQL multidimensional fatigue scale (MFS) (2-17 years old)
Time frame: Change from baseline at 6, 12, 18 and 24 months
PROMIS Fatigue Short Form questionnaire (all ages)
Time frame: Change from baseline at 6, 12, 18 and 24 months
McGill pain questionnaire (MPQ) (12 years and older)
Time frame: Change from baseline at 6, 12, 18 and 24 months
Wong-Baker Faces Pain Scale (2-11 years old)
Time frame: Change from baseline at 6, 12, 18 and 24 months
PedsQL generic quality of life (2-17 years old)
Time frame: Change from baseline at 6, 12, 18 and 24 months
Short Form 36 (SF36) quality of life scale (18 years and older)
Time frame: Change from baseline at 6, 12, 18 and 24 months
Activlim questionnaire (7-17 years old)
Time frame: Change from baseline at 6, 12, 18 and 24 months
Impact on participation and autonomy (18 years and older)
Time frame: Change from baseline at 6, 12, 18 and 24 months
Utrecht Scale for Evaluation of Rehabilitation-Participation (USER-P) (18 years and older)
Time frame: Change from baseline at 6, 12, 18 and 24 months
Borg rating scale of perceived exertion (5 years and older)
Time frame: Change from baseline at 6, 12, 18 and 24 months
Hospital anxiety and depression scale (18 years and older)
Time frame: Change from baseline at 6, 12, 18 and 24 months
PedsQL neuromuscular module (NMM) (2-17 years old)
Time frame: Change from baseline at 6, 12, 18 and 24 months
Resilience evaluation scale (18 years and older)
Time frame: Change from baseline at 6, 12, 18 and 24 months
Effects of pyridostigmine and/or salbutamol (8-60 years old) - fatigability part
Time frame: At baseline of the fatigability part of the study
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 19 Aug 2024.
- Derived from this study: PubMed 42551994van de Camp SAJH, Brenninkmeijer R, van Doorn JLM, de Laat ECM, Pomp L, Stinissen L, Cameron D, Groothuis JT, van Alfen N, Jungbluth H, Erasmus CE, Bartels B, Wadman RI, Voet NBM, van der Pol WL, Voermans NC. READYCOM: protocol for a 2-year prospective natural history and cross-sectional muscle-fatigability study for improving trial readiness in congenital myopathies. BMJ Open. 2026 Aug 4;16(8):e119529. doi: 10.1136/bmjopen-2026-119529.
- Individual participant dataSharing planned: Undecided. Research data is open access shared upon publication, provided that this complies with privacy regulations. The Donders Repository is the default repository for sharing the investigators' data.
Related trials for Central Core Disease
Recruiting
Comparison of Vestibular Stimulation and Core Stability Training on Sitting Balance in Hypotonic CP
Hypotonic Cerebral Palsy
Recruiting
SAIL-MEVO: Endovascular Treatment Versus Best Medical Therapy for Distal Vessel Occlusions
Medium Vessel Occlusion Stroke (MeVO), Stroke Acute
RecruitingPhase 2
A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)
Cognitive Dysfunction, Lewy Body Disease
Recruiting
Rapid Local Ischemic Postconditioning on Stroke After Thrombectomy
Acute Ischemic Stroke
Recruiting
Effect of Lower Limb Proprioceptive Neuromuscular Facilitation Combined With Core Stability Training Versus Proprioceptive Neuromuscular Facilitation Alone on Balance and Functional Mobility in Chronic Stroke Survivors
Stroke
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Nicol Voermans, MD PhD principal investigator
Radboud University Medical Center
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Central Core Disease and Multi-Minicore Disease, run by Radboud University Medical Center at 2 sites in Netherlands.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 11 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 19 Aug 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in Netherlands. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Nicol Voermans, MD PhD (+31650155770, Nicol.Voermans@radboudumc.nl), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change of Motor Function Measure (MFM) (time frame: Change from baseline at 6, 12, 18 and 24 months). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT06157268, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Aug 2024.